Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
VACCINEX, INC. (VCNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/04/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Attention: Mr. Maurice Zauderer, Ph.D. 1895 Mount Hope Avenue Rochester, New York 14620",
"FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT VACCINEX, INC. Warrant Shares: Initial Exercise Date: October 3, 2023 Issue Date: October 3, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until this Warrant is exercised in full , but not thereafter, to subscribe for and purchase from Vaccinex, Inc., a Delaware corporation , up to ______ shares of common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwi...",
"FORM OF COMMON STOCK PURCHASE WARRANT VACCINEX, INC. Warrant Shares: Initial Exercise Date: October 3, 2023 Issue Date: October 3, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 3, 2023 and on or prior to 5:00 p.m. on October 3, 2028 , but not thereafter, to subscribe for and purchase from Vaccinex, Inc., a Delaware corporation , up to ______ shares of common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein ...",
"Form of Securities Purchase Agreement"
09/27/2023 8-K Quarterly results
08/22/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Stock Purchase Agreement by and between the Company and the Investors",
"Registration Rights Agreement by and between the Company and the Investors"
05/19/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Hogan Lovells US LLP"
05/15/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Stock Purchase Agreement, by and between the Company and the Investors (as defined therein)"
05/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/03/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Stock Purchase Agreement by and between the Company and the Investors (as defined therein)",
"Stock Purchase Agreement by and between the Company and the Investors (as defined therein)"
03/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis"
11/25/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/11/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
09/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Neoadjuvant Pepinemab in Combination with Nivolumab and/or Ipilimumab in Resectable Stage III Melanoma",
"Neoadjuvant Pepinemab in Combination with Nivolumab and/or Ipilimumab in Resectable Stage III Melanoma"
08/08/2022 8-K Quarterly results
08/01/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer's Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer's Disease ROCHESTER, N.Y., July 29, 2022 — Vaccinex, Inc. , a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it has been selected for poster presentation related to its ongoing Phase 1/2a SIGNAL-AD study of pepinemab in patients with early Alzheimer's Disease during the upcoming 2022 Alzheimer's Association International Conference, taking place from July 31st to August 4th in San Diego via in person and virtual attendance . Details are shown below: Poster title: SEMA4D blocking antibody, pepinem...",
"AAIC 22 Poster: SEMA4D blocking antibody, pepinemab, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports ongoing clinical development in Phase 1b/2a AD Study"
06/10/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
04/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/08/2022 8-K Quarterly results
01/31/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Stock Purchase Agreement by and between the Company and the Investors (as defined therein), Amendment to Stock Purchase Agreement by and between the Company and the Investors signatory thereto, and Joinders by and between the Company and the Additional Investors signatory thereto",
"Registration Rights Agreement by and between the Company and the Investors (as defined therein)",
"Vaccinex Announces $6.6 Million Private Placement"
01/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA ® in Patients with Recurrent or Metastatic Head and Neck Cancer ROCHESTER, N.Y., January 26, 2022 — Vaccinex, Inc. , a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D , today reported positive interim response data in the Phase Ib segment of the KEYNOTE-B84 study of Vaccinex's pepinemab in combination with Merck's anti-PD-1 therapy KEYTRUDA ® in patients with recurrent or metastatic head and neck squamous cell carcinoma . Among the three patients enrolled in the Phase1b safety segment of the study, two patients have been observe..."
08/03/2021 8-K Termination of a Material Definitive Agreement  Interactive Data
05/17/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
02/19/2021 8-K Quarterly results
10/26/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 22, 2020 Vaccinex, Inc. Delaware 001-38624 16-1603202 1895 Mount Hope Avenue, Rochester, New York 14620 271-2700 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange A..."
09/22/2020 8-K Quarterly results
09/09/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Opinion of Hogan Lovells US LLP",
"Opinion of Hogan Lovells US LLP"
08/27/2020 8-K Quarterly results
08/14/2020 8-K Quarterly results
07/31/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy